Phreesia announced that its contract with the CMS Innovation Center for use of the Patient Activation Measure has been renewed through 2029. The PAM performance measure, which assesses gains in patients’ knowledge, skills and confidence in managing their own healthcare, is one of the first patient-reported outcome performance measures used in a CMS alternative payment model. Under the new contract, Phreesia will provide access to PAM, training, analysis and other support to the Kidney Care Choices Model. CMMI also has the option to expand the PAM into additional models, including those focused on other disease states, care settings or episodes of care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia (PHR) Improves Healthcare Outcomes and Expects Growing Clientele
- Phreesia price target raised to $28 from $27 at JPMorgan
- Phreesia price target raised to $31 from $29 at Truist
- Phreesia price target raised to $34 from $31 at Baird
- Closing Bell Movers: C3.ai falls 16% with guidance unchanged despite Q1 beat
